摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,4',4''-次甲基三[N,N-二丙基苯胺] | 60813-12-9

中文名称
4,4',4''-次甲基三[N,N-二丙基苯胺]
中文别名
——
英文名称
Benzenamine, 4,4',4''-methylidynetris[N,N-dipropyl-
英文别名
4-[bis[4-(dipropylamino)phenyl]methyl]-N,N-dipropylaniline
4,4',4''-次甲基三[N,N-二丙基苯胺]化学式
CAS
60813-12-9
化学式
C37H55N3
mdl
——
分子量
541.9
InChiKey
UXBWXMXAXJKBSA-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    11
  • 重原子数:
    40
  • 可旋转键数:
    18
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.51
  • 拓扑面积:
    9.7
  • 氢给体数:
    0
  • 氢受体数:
    3

文献信息

  • MELANIN PRODUCTION INHIBITOR
    申请人:Yokoyama Kouji
    公开号:US20110243865A1
    公开(公告)日:2011-10-06
    Disclosed is a melanin production inhibitor which has an excellent inhibitory activity on the production of melanin and is highly safe. The melanin production inhibitor comprises a compound represented by general formula (1) (excluding clotrimazole), and/or a pharmacologically acceptable salt thereof. In the formula, A1, A2 and A3 are independently selected from a hydrogen atom, an aryl group which may have a substituent, and an aromatic heterocyclic group which may have a substituent, wherein at least one of A1, A2 and A3 is selected from the aryl group and the aromatic heterocyclic group, the total number of carbon atoms contained in A1, A2 and A3 is 6 to 50 and, when at least two of A1, A2 and A3 represent the aryl groups or the aromatic heterocyclic groups, the adjacent two aryl or aromatic heterocyclic groups may be bound to each other via an alkyl chain or an alkenyl chain to form a ring; m represents an integer of 0 to 2; X represents a hetero atom, a hydrogen atom, or a carbon atom; R1 and R2 are independently selected from a hydrogen atom and an oxo group, wherein when one of R1 and R2 is an oxo group, the other is not present; and R3 is selected from a hydrogen atom, and a C 1-8 hydrocarbon group in which one or some of hydrogen atoms or carbon atoms may be substituted by a hetero atom or hetero atoms, wherein the number of R3's present in the compound corresponds to the number of X's and, when two or more R3's are present, the R3's are independently present and the adjacent two R3's may be bound to each other to form, together with X, a ring, and the terminal of R3 may be bound to a carbon atom to which A1, A2 and A3 are bound, thereby forming a ring.
    披露了一种黑色素生产抑制剂,它对黑色素的生产具有出色的抑制活性且高度安全。该黑色素生产抑制剂包括由通用公式(1)表示的化合物(不包括克霉唑)和/或其药理上可接受的盐。在公式中,A1、A2和A3独立地选自氢原子、可能带有取代基的芳基团和可能带有取代基的芳香杂环团,其中至少A1、A2和A3之一选自芳基团和芳香杂环团,A1、A2和A3中包含的碳原子总数为6至50,并且当至少两个A1、A2和A3表示芳基团或芳香杂环团时,相邻的两个芳基或芳香杂环团可以通过烷基链或烯基链相互连接形成环;m代表0至2的整数;X代表异原子、氢原子或碳原子;R1和R2独立地选自氢原子和氧代基,其中当R1和R2之一是氧代基时,另一个不出现;R3选自氢原子和C 1-8 碳氢化合物组,其中一些或所有的氢原子或碳原子可能被异原子或异原子取代,其中化合物中存在的R3的数量对应于X的数量,并且当存在两个或更多R3时,R3独立地存在,并且相邻的两个R3可以相互连接以与X一起形成环,并且R3的末端可以与A1、A2和A3连接的碳原子结合,从而形成环。
  • [EN] 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE DERIVATIVES AS ANTIPSYCHOTIC AGENTS<br/>[FR] DERIVES DE LA 7-PHENYLSULFONYL-TETRAHYDRO-3-BENZAZEPINE AGENTS ANTIPSYCHOTIQUES
    申请人:GLAXO GROUP LTD
    公开号:WO2005051398A1
    公开(公告)日:2005-06-09
    The invention provides one or more chemical entities selected from a compound of formula (I): wherein R1 represents C1-6alkyl, C1-6alkoxy, trifluoromethyl, trifluoromethoxy, halo, cyano, 5-methyl-1,2,4-oxadiazol-3-yl or a group -SO2X; R2 represents hydrogen, C1-6alkyl, C1-6alkoxy, halo or cyano; X is C1-6alkyl, -NR3R4 or morpholino; R3 and R4 independently represent hydrogen or C1-6alkyl; and a pharmaceutically acceptable salt and solvate thereof; with the proviso that the compound 8-[4-(4-fluoro-benzyl)-benzenesulfonyl]-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl}-dimethyl-amine is excluded. The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof are useful in therapy, in particular as antipsychotic agents.
    该发明提供了一种或多种从化合物的化学实体,该化合物的结构如下(I):其中R1代表C1-6烷基,C1-6烷氧基,三甲基,三甲氧基,卤素,基,5-甲基-1,2,4-噁二唑-3-基或基团-SO2X;R2代表氢,C1-6烷基,C1-6烷氧基,卤素或基;X代表C1-6烷基,-NR3R4或吗啡啉;R3和R4独立地代表氢或C1-6烷基;以及其药学上可接受的盐和溶剂;但化合物8-[4-(4-苄基)-苯甲磺酰]-3-甲基-2,3,4,5-四氢-1H-3-苯并哌啶-7-基}-二甲胺被排除。该式(I)的化合物及其药学上可接受的盐和溶剂在治疗中很有用,特别是作为抗精神病药物。
  • Preparation of prodrugs for selective drug delivery
    申请人:Mills L. Randell
    公开号:US20050080260A1
    公开(公告)日:2005-04-14
    Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.
    合成具有A-B-C化学式的化合物,可用于药物传递等应用,其中A是化学发光基团,B是光致变色基团,C是生物活性基团,其中A-B-C可作为前药。本发明的新型合成方法用于形成前药,包括以下步骤:(1)形成苯酮,(2)形成二芳基乙烯,(3)将邻苯二甲酰亚胺基团连接到乙烯的至少一个芳基上,形成邻苯二甲酰亚胺-乙烯共轭物,(4)缩合两个乙烯-邻苯二甲酰亚胺共轭物,形成邻苯二甲酰亚胺-戊二烯共轭物,(5)通过与反应将邻苯二甲酰亚胺转化为邻苯二酰,形成本发明的载体化合物,(6)将载体化合物与药物的亲核基团反应,形成相应的前药。另外,可以通过使用卤代二芳基乙烯制备相应的阳离子类似的类似类似染料化合物。然后,通过与亲核试剂反应保护阳离子类似化合物,并通过催化的胺化与基邻苯二甲酰亚胺偶联,形成保护的邻苯二甲酰亚胺-戊二烯共轭物。后者与回流,将其邻苯二甲酰亚胺转化为邻苯二酰,并酸化以得到载体。本发明的另一个方面涉及将这些化合物用作抗病毒剂,用于治疗病毒感染,如HIV,以及用作抗癌剂,用于治疗结肠癌、肺癌和乳腺癌等癌症。
  • Titanocene based compound, photosensitive composition, photosensitive transfer sheet and pattern forming method
    申请人:Sugiyama Takekatsu
    公开号:US20070212642A1
    公开(公告)日:2007-09-13
    A titanocene compound having a carbonyl group, and a photosensitive composition whose sensitivity has been enhanced by containing this as a photopolymerization initiator, a photosensitive transfer sheet using said photosensitive composition, and a pattern forming method using said photosensitive transfer sheet are provided.
    提供了一种含有羰基的环化合物,以及一种光敏组合物,其中包含该环化合物作为光聚合引发剂,已增强其敏感度,使用该光敏组合物的光敏转移膜和使用该光敏转移膜的图案形成方法。
  • 7-Phenylsulfonyl-Tetrahydro-3-Benzazepine Dervatives as Antipsychotic Agents
    申请人:Forbes Thomson Ian
    公开号:US20070225276A1
    公开(公告)日:2007-09-27
    The invention provides one or more chemical entities selected from a compound of formula (I): wherein R 1 represents C 1-6 alkyl, C 1-6 alkoxy, trifluoromethyl, trifluoromethoxy, halo, cyano, 5-methyl-1,2,4-oxadiazol-3-yl or a group —SO 2 X; R 2 represents hydrogen, C 1-6 alkyl, C 1-6 alkoxy, halo or cyano; X is C 1-6 alkyl, —NR 3 R 4 or morpholino; R 3 and R 4 independently represent hydrogen or C 1-6 alkyl; and a pharmaceutically acceptable salt and solvate thereof; with the proviso that the compound 8-[4-(4-fluoro-benzyl)-benzenesulfonyl]-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl}-dimethyl-amine is excluded. The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof are useful in therapy, in particular as antipsychotic agents.
    本发明提供了一种或多种化学实体,所述化学实体从式(I)的化合物中选择:其中,R1代表C1-6烷基,C1-6烷氧基,三甲基,三甲氧基,卤素,基,5-甲基-1,2,4-噁二唑-3-基或基团-SO2X;R2代表氢,C1-6烷基,C1-6烷氧基,卤素或基;X代表C1-6烷基,-NR3R4或吗啡环;R3和R4独立地代表氢或C1-6烷基;以及其药学上可接受的盐和溶剂,但式8-[4-(4-氟苯甲基)-苯磺酰基]-3-甲基-2,3,4,5-四氢-1H-3-苯并氮杂环-7-基}-二甲基胺被排除在外。式(I)的化合物及其药学上可接受的盐和溶剂在治疗中有用,特别是作为抗精神病药物。
查看更多

同类化合物

(3-三苯基甲氨基甲基)吡啶 非马沙坦杂质1 隐色甲紫-d6 隐色孔雀绿-d6 隐色孔雀绿 隐色乙基结晶紫 降钙素杂质10 重氮四苯基乙烷 酸性黄117 酸性蓝119 酚酞啉 酚酞二硫酸钾水合物 萘,1-甲氧基-3-甲基 苯酚,4-(1,1-二苯基丙基)- 苯甲醇,4-溴-a-(4-溴苯基)-a-苯基- 苯甲醇,2-氨基-5-氯-a-乙烯基-a-苯基- 苯甲酸,4-(羟基二苯甲基)-,甲基酯 苯甲酸,3-[[2-[[(1,1-二甲基乙氧基)羰基]氨基]-3-[(三苯代甲基)硫代]丙基]氨基]-,(R)- 苯甲基N-[(2(三苯代甲基四唑-5-基-1,1联苯基-4-基]-甲基-2-氨基-3-甲基丁酸酯 苯基双-(对二乙氨基苯)甲烷 苯基二甲苯基甲烷 苯基二[2-甲基-4-(二乙基氨基)苯基]甲烷 苯基{二[4-(三氟甲基)苯基]}甲醇 苯基-二(2-羟基-5-氯苯基)甲烷 苄基2,3,4-三-O-苄基-6-O-三苯甲基-BETA-D-吡喃葡萄糖苷 苄基 5-氨基-5-脱氧-2,3-O-异亚丙基-6-O-三苯甲基呋喃己糖苷 苄基 2-乙酰氨基-2-脱氧-6-O-三苯基-甲基-alpha-D-吡喃葡萄糖苷 苄基 2,3-O-异亚丙基-6-三苯甲基-alpha-D-甘露呋喃糖 苄基 2,3,4-三-O-(苯基甲基)-6-O-(三苯基甲基)-ALPHA-D-吡喃甘露糖苷 芴甲氧羰基-4-叔丁酯-天冬酰胺-S-三氯苯甲基-L-半胱氨酸 膦酸,1,2-乙二基二(磷羧基甲基)亚氨基-3,1-丙二基次氮基<三价氮基>二(亚甲基)四-,盐钠 脱氢奥美沙坦-2三苯甲基奥美沙坦脂 美托咪定杂质28 绿茶提取物茶多酚陕西龙孚 结晶紫 磺基琥珀酰亚胺基-4-[2-(4,4-二甲氧基三苯甲基)]丁酸酯 磷,三(4-甲氧苯基)甲基-,碘化 碱性蓝 硫代硫酸氢 S-[2-[(3,3,3-三苯基丙基)氨基]乙基]酯 盐酸三苯甲基肼 白孔雀石绿-d5 甲酮,(反-4-氨基-4-甲基环己基)-4-吗啉基- 甲基三苯基甲基醚 甲基6-O-(三苯基甲基)-ALPHA-D-吡喃甘露糖苷三苯甲酸酯 甲基3,4-O-异亚丙基-6-O-三苯甲基-beta-D-吡喃半乳糖苷 甲基3,4-O-异亚丙基-2-O-甲基-6-O-三苯甲基吡喃己糖苷 甲基2-甲基-N-{[4-(三氟甲基)苯基]氨基甲酰}丙氨酸酸酯 甲基2,3,4-三-O-苯甲酰基-6-O-三苯甲基-ALPHA-D-吡喃葡萄糖苷 甲基2,3,4-三-O-苄基-6-O-三苯甲基-ALPHA-D-吡喃葡萄糖苷 甲基2,3,4-三-O-(苯基甲基)-6-O-(三苯基甲基)-ALPHA-D-吡喃半乳糖苷